Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

About Us
Get in touch
Background

About us

Our Commitment to ESG

At Sygnature Discovery, Environmental, Social, and Governance (ESG) principles guide our core strategies and decision-making. We believe sustainability is not just a responsibility – it’s an integral part of how we operate.

Get in touch

Our Journey to Net Zero

We’re committed to achieving Net Zero, and every team member plays a role in this mission. To support engagement, we’ve established initiatives such as Green Science Groups and Sustainability Committees, ensuring collaboration and accountability across the organization.

SBTi Commitment – January 2025

In January 2025, Sygnature Discovery formally registered its commitment with the Science Based Targets initiative (SBTi) to set both near-term and Net Zero targets. This milestone underscores our determination to reduce greenhouse gas (GHG) emissions in line with climate science.

EcoVadis Bronze Medal – April 2025

In April 2025, Sygnature Discovery earned the EcoVadis Bronze Medal, placing us among the top 35% of companies assessed globally. This recognition reflects the strength of our sustainability management system and our measurable impact.

A Message from Our CEO

“As an industry leader, we have a responsibility to set the standard for sustainable excellence. We are committed to minimizing our environmental footprint, promoting ethical practices, and fostering social responsibility throughout our operations.”

Dr Simon Hirst

CEO of Sygnature Discovery

Featured image for testimonial by Dr Simon Hirst

Supplier Code of Conduct and Ethics 

Corporate integrity, responsible sourcing, and worker health and safety across our global supply chain are non-negotiable priorities. These principles form the foundation of our Supplier Code of Conduct and Ethics, which defines the minimum standards expected from every business or entity that provides products or services to Sygnature Discovery.Our standards are built on three core pillars: Environmental Impact, Social Responsibility, and Good Governance. Here’s what that means:

Environmental Impact

  • Commitment to minimizing environmental impact and reducing carbon footprint.
  • Compliance with all applicable environmental laws and international treaties, including those related to climate change, waste disposal, emissions, discharges, and handling of hazardous materials.
  • Ongoing evaluation of opportunities to reduce energy consumption, promote recycling, and set measurable reduction targets.

Social Responsibility

  • Zero tolerance for modern slavery, human trafficking, and forced labor.
  • Full compliance with internationally recognized human rights standards.
  • Equal opportunity for all, with zero tolerance for discrimination in any employment practice.
  • Respect for freedom of association and collective bargaining.
  • Safe, healthy, and sanitary working conditions.
  • Payment of wages and benefits that meet or exceed legal requirements.

Good Governance

  • Strong measures to protect the integrity and confidentiality of information, including commercial data and employee privacy.
  • Zero tolerance for bribery and corruption, with clear procedures for managing gifts and hospitality.
  • Compliance with all applicable laws, statutes, codes, and regulations, including competition laws.
  • Transparent supplier compliance monitoring and fair payment terms.

Our Gender Pay Gap

We’re committed to creating equal opportunities for all employees. That’s why we’re taking proactive steps to close our gender pay gap. We believe transparency matters, so we regularly publish our gender pay gap data to share our progress and highlight the work still ahead.